DSM Biologics to Acquire Rhobust Technology from Upfront Chromatography

DSM Biologics, a business unit of DSM Pharmaceutical products, said it has reached an agreement for the acquisition of the assets and associated business of the Rhobust technology from Danish Upfront Chromatography for pharmaceutical and other applications.

As a result of the acquisition, DSM Biologics will gain all rights for the commercialization of the Rhobust technology in various fields, including the pharma industry. The Rhobust technology will lead to further innovation in the downstream processing for the manufacturing of recombinant proteins and antibodies. DSM Biologics will continue to support all existing clients for this technology.

The parties have agreed to not disclose financial details.

Company

DSM Pharmaceutical Products

45 Waterview Blvd.
Parsippany, NJ 07054-1298

Company contact







Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

most read